Cystic fibrosis transmembrane conductance regulator
The cystic fibrosis transmembrane conductance regulator (CFTR) is an ATP-binding cassette (ABC) transporter-class ion channel encoded by the CFTR gene on human chromosome 7q31.2.
The cystic fibrosis transmembrane conductance regulator (CFTR) is an ATP-binding cassette (ABC) transporter-class ion channel encoded by the CFTR gene on human chromosome 7q31.2. The protein functions primarily as a regulated chloride and bicarbonate anion channel expressed at the apical surface of epithelial cells lining the airways, intestine, pancreatic ducts, sweat glands, and reproductive tract. CFTR channel gating is controlled by phosphorylation of its regulatory (R) domain and by ATP binding and hydrolysis at its two nucleotide-binding domains. When CFTR function is lost or severely diminished — due to any of more than 2,000 identified pathogenic variants in the CFTR gene — chloride transport across epithelial membranes is disrupted, leading to the accumulation of abnormally thick, dehydrated mucus and the multisystem disease known as cystic fibrosis (CF).
CF is one of the most common life-limiting autosomal recessive disorders in populations of Northern European descent, affecting the respiratory system most critically through cycles of mucus obstruction, bacterial infection, and progressive inflammation, while also causing pancreatic exocrine insufficiency, intestinal dysmotility, hepatobiliary disease, and male infertility. The severity and organ distribution of disease depend heavily on the specific class of CFTR mutation carried by an individual. Class I mutations result in absent or nonfunctional protein, often through premature termination or defective splicing; Class II mutations (most notably F508del, the most prevalent CF allele) cause misfolding and premature proteasomal degradation; Class III mutations impair channel gating; and Classes IV–VI affect conductance, expression levels, or protein stability. This mutation-class framework has become central to the development and clinical stratification of CFTR-targeting pharmacotherapies, broadly termed CFTR modulators.
Where the papers sit
9 papers from the last 6 months study cystic fibrosis transmembrane conductance regulator directly · updated from PubMed 12 Nov 2026
Study type 0 clinical trials · 4 observational · 2 human data · 2 preclinical · 1 unclassified
Themes one subject
Those 9 are all about one subject.
-
CFTR Modulation and Care
CFTR-directed care is moving toward earlier treatment, broader eligibility and more durable correction of function. Elexacaftor/tezacaftor/ivacaftor and Alyftrek show high-potency rescue, with early modulation linked to improved clinical outcomes and reduced systemic antibiotic use. For variants not adequately treated by modulators, chemically modified tRNA delivery and basal-cell transplantation offer experimental routes to restore CFTR activity. Functional sensing, long-term comparisons and vaccine uptake remain important for measuring benefit and closing gaps in care.
Papers
The 9 papers from the last 6 months that study cystic fibrosis transmembrane conductance regulator directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
CFTR Modulation and Care (9)
- Non-eligibility for highly effective modulator therapy with elexacaftor/tezacaftor/ivacaftor in cystic fibrosis: What about Portugal? Pulmonology · 20 Oct 2026 PMID 42898061
- Early CFTR modulation and clinical outcomes in preschool cystic fibrosis. Pediatric research · 2 Sept 2026 PMID 42680797
- Nonviral delivery of chemically modified tRNA rescues nonsense mutations in cystic fibrosis. Science (New York, N.Y.) · 27 Aug 2026 PMID 42658930
- Functional and biochemical characterization of Alyftrek components reveals high-potency rescue of F508del-CFTR. American journal of physiology. Lung cellular and molecular physiology · 19 Aug 2026 PMID 42616613
- Basal cell transplantation supports multilineage differentiation and restores CFTR function in ex vivo ferret airways. JCI insight · 18 Aug 2026 PMID 42611556
- Impact of Elexacaftor/Tezacaftor/Ivacaftor on Systemic Antibiotic Utilization in Pediatric Patients With Cystic Fibrosis. Pediatric pulmonology · 28 Jul 2026 PMID 42517727
- Suboptimal vaccine coverage for preventable respiratory infections in children with cystic fibrosis in the Cystic Fibrosis Regional Reference Centre of Tuscany: Need for improving preventive strategies. Human vaccines & immunotherapeutics · 29 Jun 2026 PMID 42373575
- Toward Precision Electrochemical Sensing of CFTR Function in Cystic Fibrosis Models. Analytical chemistry · 4 Jun 2026 PMID 42240701
- Comparison of Long Term Effects of Treatment of Different CFTR Modulators in People With Cystic Fibrosis. Pediatric pulmonology · 28 May 2026 PMID 42206906
By study type
Observational studies and case reports (4)
- Non-eligibility for highly effective modulator therapy with elexacaftor/tezacaftor/ivacaftor in cystic fibrosis: What about Portugal? Pulmonology · 20 Oct 2026 PMID 42898061
- Impact of Elexacaftor/Tezacaftor/Ivacaftor on Systemic Antibiotic Utilization in Pediatric Patients With Cystic Fibrosis. Pediatric pulmonology · 28 Jul 2026 PMID 42517727
- Suboptimal vaccine coverage for preventable respiratory infections in children with cystic fibrosis in the Cystic Fibrosis Regional Reference Centre of Tuscany: Need for improving preventive strategies. Human vaccines & immunotherapeutics · 29 Jun 2026 PMID 42373575
- Comparison of Long Term Effects of Treatment of Different CFTR Modulators in People With Cystic Fibrosis. Pediatric pulmonology · 28 May 2026 PMID 42206906
Human data, design not indexed (2)
- Functional and biochemical characterization of Alyftrek components reveals high-potency rescue of F508del-CFTR. American journal of physiology. Lung cellular and molecular physiology · 19 Aug 2026 PMID 42616613
- Toward Precision Electrochemical Sensing of CFTR Function in Cystic Fibrosis Models. Analytical chemistry · 4 Jun 2026 PMID 42240701
Preclinical: animal, cell and lab studies (2)
- Nonviral delivery of chemically modified tRNA rescues nonsense mutations in cystic fibrosis. Science (New York, N.Y.) · 27 Aug 2026 PMID 42658930
- Basal cell transplantation supports multilineage differentiation and restores CFTR function in ex vivo ferret airways. JCI insight · 18 Aug 2026 PMID 42611556
Unclassified: not yet indexed with MeSH (1)
- Early CFTR modulation and clinical outcomes in preschool cystic fibrosis. Pediatric research · 2 Sept 2026 PMID 42680797
Written from 9 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-08-29 by GPT. Corrections: 2026-09-26 by GPT. Drafted by language models from published abstracts; not medical advice.